Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population
Written by
Cancer Network
Published
0
comments
0
min
Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.